BNGO logo

Bionano Genomics Inc. (BNGO)

$1.26

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BNGO

Market cap

$14458500

EPS

-4.46

P/E ratio

--

Price to sales

0.5

Dividend yield

--

Beta

1.650623

Price on BNGO

Previous close

$1.25

Today's open

$1.25

Day's range

$1.23 - $1.27

52 week range

$1.06 - $5.50

Profile about BNGO

CEO

Al Luderer

Employees

344

Headquarters

San Diego, CA

Exchange

NASDAQ Capital Market

Shares outstanding

11475000

Issue type

Common Stock

BNGO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BNGO

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.

news source

GlobeNewsWire • May 28, 2026

news preview

Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors

Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

news source

Zacks Investment Research • May 28, 2026

news preview

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM's potential to transform how this aggressive blood cancer is studied and understood.

news source

GlobeNewsWire • May 26, 2026

news preview

Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 13, 2026

news preview

Bionano Reports First Quarter 2026 Results and Provides a Business Update

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D.

news source

GlobeNewsWire • May 13, 2026

news preview

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago.

news source

Zacks Investment Research • May 13, 2026

news preview

Bionano Announces Leadership Transition

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer will continue to serve as chairman, and director Chris Twomey will serve as Lead Independent Director. He succeeds Erik Holmlin, PhD, who is staying on as an advisor. The company anticipates a seamless transition without business disruption.

news source

GlobeNewsWire • May 6, 2026

news preview

Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025

Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic Insights OGM Can Identify Actionable Disrupted Genes Across Rare Diseases SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) reported that 28 publications describing the utility of optical genome mapping (OGM) for analysis of rare diseases were released in Q1 2026, representing an approximately 56% increase over last year. The total number of samples analyzed, 78, represents a 225% increase compared to the number analyzed in studies published in Q1 2025 (24).

news source

GlobeNewsWire • May 5, 2026

news preview

Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2026 and to highlight recent corporate progress.

news source

GlobeNewsWire • Apr 29, 2026

news preview

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma (MM), a complex hematologic malignancy known for its low success rate when analyzed by traditional cytogenetic methods. The multicenter study, led by scientists from Johns Hopkins University School of Medicine and The University of Texas MD Anderson Cancer Center, found that OGM performed on real-world clinical research samples was concordant with traditional methods, had a higher overall success rate for finding pathogenic or likely pathogenic abnormalities, and yielded a result for a substantial fraction of samples that failed to reveal an answer using traditional workflows, overcoming limitations of MM analysis by techniques such as fluorescence in situ hybridization (FISH), karyotyping, and next-generation sequencing (NGS).

news source

GlobeNewsWire • Apr 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Bionano Genomics Inc.

Open an M1 investment account to buy and sell Bionano Genomics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BNGO on M1